Organon (NYSE: OGN), a specialist in women’s health, has in-licensed migraine treatments Emgality (galcanezumab) and Rayvow (lasmiditan) from U.S. partner Eli Lilly (NYSE: LLY) for the European market. Under the agreement, Lilly will receive an upfront payment of $50 million, along with milestone payments, pending regulatory approval expected in Q1 2024.
According to the public data, Emgality was one of Lilly’s top-selling products in Q3 2023, achieving global sales of $168 million, which includes $42.1 million from markets outside the U.S.
Emgality is a biologic therapy designed to prevent migraine episodes by blocking the calcitonin gene-related peptide (CGRP), while Rayvow is a first-in-class serotonin 5-HT1F receptor agonist intended for the treatment of migraine attacks, with or without aura.- Flcube.com
